Compass Therapeutics (CMPX) Long-Term Debt Repayments (2020 - 2021)
Compass Therapeutics recorded quarterly Long-Term Debt Repayments of $3.8 million in Q4 2021, up 100.0% quarter-over-quarter from $1.9 million in Q3 2021.
Compass Therapeutics' Long-Term Debt Repayments history runs 2 years deep, the most recent figure standing at $3.8 million for Q4 2021.
- In Q4 2021, Long-Term Debt Repayments changed N/A year-over-year to $3.8 million; the TTM figure through Sep 2022 stood at $3.8 million (down 60.0% YoY), while the FY2021 annual figure was $9.4 million, up 66.67% from the prior year.
- Long-Term Debt Repayments came in at $3.8 million for Q4 2021 at Compass Therapeutics, up from $1.9 million in the prior quarter.
- In the past five years, Long-Term Debt Repayments ranged from a high of $3.8 million in Q3 2020 to a low of $1.9 million in Q2 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Compass Therapeutics | 418.47 Mn | 223.78 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 3.75 Mn |
| Dec 31, 2021 | 3.75 Mn |
| Sep 30, 2021 | 1.88 Mn |
| Sep 30, 2021 | 1.88 Mn |
| Jun 20, 2021 | 1.88 Mn |
| Jun 20, 2021 | 1.88 Mn |
| Mar 31, 2021 | 1.88 Mn |
| Mar 31, 2021 | 1.88 Mn |
| Sep 30, 2020 | 3.75 Mn |
| Sep 30, 2020 | 3.75 Mn |
| Jun 30, 2020 | 1.88 Mn |
| Jun 30, 2020 | 1.88 Mn |